Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Novel agents and new therapeutics in castration-resistant prostate cancer.

Wu Y, Rosenberg JE, Taplin ME.

Curr Opin Oncol. 2011 May;23(3):290-6. doi: 10.1097/CCO.0b013e3283449400. Review.

PMID:
21311328
2.

Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer.

Barginear MF, Raptis G.

Expert Rev Anticancer Ther. 2010 Feb;10(2):149-51. doi: 10.1586/era.09.174.

PMID:
20131991
3.

Foreword. Poly(ADP-ribose) polymerase inhibitors in clinical development.

Kummar S.

Curr Probl Cancer. 2011 Jan-Feb;35(1):6. doi: 10.1016/j.currproblcancer.2010.12.001. No abstract available.

PMID:
21300206
4.

Novel agents and future directions for refractory breast cancer.

Burstein HJ.

Semin Oncol. 2011 Jun;38 Suppl 2:S17-24. doi: 10.1053/j.seminoncol.2011.04.002. Review.

PMID:
21600381
5.

Chemotherapy in patients with castration-resistant prostate cancer.

Meulenbeld HJ, Hamberg P, de Wit R.

Eur J Cancer. 2009 Sep;45 Suppl 1:161-71. doi: 10.1016/S0959-8049(09)70029-2. Review. No abstract available.

PMID:
19775615
6.

Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.

Trofimova I, Dimtchev A, Jung M, Rosenthal D, Smulson M, Dritschilo A, Soldatenkov V.

Cancer Res. 2002 Dec 1;62(23):6879-83.

7.

PARP inhibitors in breast cancer.

Telli ML, Ford JM.

Clin Adv Hematol Oncol. 2010 Sep;8(9):629-35. Review.

PMID:
21157412
8.

Combined castration and androgen blockade therapy in prostate cancer. Conclusions.

Denis L, Mettlin C.

Cancer. 1990 Sep 1;66(5 Suppl):1086-9. Review. No abstract available.

9.

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.

Urology. 2003 Jul;62(1):99-104.

PMID:
12837431
10.

Targeted therapy for advanced prostate cancer: Looking through new lenses.

Vogiatzi P, Cassone M, Claudio L, Claudio PP.

Drug News Perspect. 2009 Dec;22(10):593-601. doi: 10.1358/dnp.2009.10.1428872. Review.

PMID:
20140279
11.

State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey.

DiPaola RS, Kumar P, Hait WN, Weiss RE.

N J Med. 2001 Feb;98(2):23-33. Review.

PMID:
11221439
12.

Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer.

Kondapaka BS, Reddy KB.

Mol Cell Endocrinol. 1996 Mar 1;117(1):53-8.

PMID:
8734473
13.

Inhibition of poly(ADP-ribose) polymerase in cancer.

Plummer ER.

Curr Opin Pharmacol. 2006 Aug;6(4):364-8. Epub 2006 Jun 5. Review.

PMID:
16753340
14.

Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.

Lewis C, Low JA.

Curr Opin Investig Drugs. 2007 Dec;8(12):1051-6. Review.

PMID:
18058575
15.

Re: Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur urol 2011;60:279-90.

Braillon A.

Eur Urol. 2011 Oct;60(4):e33. doi: 10.1016/j.eururo.2011.06.054. Epub 2011 Jul 13. No abstract available.

PMID:
21767907
16.

Castration-refractory prostate cancer: New drugs in the pipeline.

Schrijvers D, Van Erps P, Cortvriend J.

Adv Ther. 2010 May;27(5):285-96. doi: 10.1007/s12325-010-0038-1. Epub 2010 Jun 4. Review.

PMID:
20532721
17.

Role of targeted therapy in the treatment of advanced prostate cancer.

Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M.

BJU Int. 2010 Mar;105(6):748-67. doi: 10.1111/j.1464-410X.2010.09236.x. Review.

18.

Targeted therapies in breast cancer: where are we now?

Di Cosimo S, Baselga J.

Eur J Cancer. 2008 Dec;44(18):2781-90. doi: 10.1016/j.ejca.2008.09.026. Epub 2008 Nov 14. Review.

PMID:
19013786
19.

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.

Clin Cancer Res. 1998 Aug;4(8):1887-98.

20.

Supplemental Content

Support Center